Trial Profile

Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management. The MINERVA Trial - A Phase IV Trial

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 18 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Anastrozole (Primary) ; Exemestane (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms MINERVA

22 Dec 2023 Planned End Date changed from 1 Apr 2026 to 1 Apr 2029.
22 Dec 2023 Planned primary completion date changed from 1 Apr 2026 to 1 Apr 2029.
11 May 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com